Imagine the thrill of a medical breakthrough that could save countless lives from a virus that has long haunted families worldwide—respiratory syncytial virus (RSV), a common culprit behind severe respiratory illnesses, especially in babies and the elderly. In 2025, advancements in RSV prevention didn't just make headlines; they reshaped how we protect our most vulnerable populations. But here's where it gets exciting: Discover how new vaccines and monoclonal antibodies turned the tide against this stubborn foe, offering hope where there was once only worry. And this is the part most people miss—the real-world impacts that show these innovations aren't just theories, but life-saving realities. Let's dive into the top RSV content from AJMC.com for 2025, exploring the pivotal studies and approvals that highlighted the transformative power of prevention.
The landscape of respiratory syncytial virus (RSV) research and prevention was utterly transformed in 2025, largely thanks to compelling evidence from studies demonstrating the broad advantages of vaccination for older adults, infants, and newborns. For instance, among seniors, research revealed that immunizations prevented a staggering number of deaths and serious respiratory cases, while in the younger crowd, options like nirsevimab (approved in July 2023) and clesrovimab (approved in June 2025) emerged as dependable shields during their initial encounter with the virus. To put it simply, RSV is a virus that can cause mild cold-like symptoms in healthy adults but often leads to severe issues like pneumonia or bronchiolitis in infants and older folks, making these preventive tools a game-changer for public health.
Here are the top 5 RSV articles featured on AJMC.com for 2025, each unpacking critical insights with data-driven precision:
- Increasing RSV Vaccination Among Older Adults Has the Potential to Spare Thousands of Lives
Published in October, this piece celebrated the advantages of RSV vaccination for adults aged 60 and up, emphasizing how it slashes instances of lower respiratory tract disease (LRTD)—that's basically infections affecting the lungs and airways—along with hospitalizations and fatalities. Spanning from August 2023 to July 2028, researchers used a multicohort Markov model to simulate scenarios with or without the adjuvanted RSVPreF3 vaccine. Their findings indicated that vaccinating 13.4 million older Americans could avert over 700,000 cases of RSV-related LRTD and more than 6,000 deaths. To help beginners grasp this, a Markov model is like a mathematical tool that predicts health outcomes over time, factoring in probabilities of events like illness or recovery. In June 2024, guidelines evolved to advise a single dose for those 75 and older, plus those 60-74 at higher risk for severe illness.
But here's where it gets controversial—should vaccination be mandatory for seniors, or does personal choice trump public health imperatives? Many argue the benefits outweigh individual freedoms, yet others worry about overreach. What do you think? Share your views in the comments.
Read the full article at https://www.ajmc.com/view/boosting-rsv-vaccination-in-older-adults-could-save-thousands.
- Evidence from Everyday Use Demonstrates Nirsevimab's Role in Cutting Infant RSV Hospitalizations
Nirsevimab (Beyfortus, from Sanofi), a long-lasting monoclonal antibody, continues to earn strong endorsements for warding off RSV-related hospital stays in babies under 8 months, based on a study assessing its real-world effectiveness. Analyzing data from the 2024-2025 RSV season for 409,723 infants born between February 1, 2024, and January 31, 2025—nearly half (47.5%) received the treatment—results showed vaccinated infants faced a 0.4% hospitalization rate compared to 1.2% for unvaccinated ones. This translated to hazard ratios of 0.29 unadjusted and 0.23 adjusted, meaning 71% and 77% reductions in risk, respectively. For those new to medical stats, a hazard ratio compares event risks between groups; here, it's a clear sign of protection.
Read the full article at https://www.ajmc.com/view/real-world-data-show-preventive-nirsevimab-reduces-infant-rsv-hospitalizations.
- Rates of Infant RSV Hospitalizations Plummeted in the Inaugural Season of Broad Preventive Measures
In comparison to pre-COVID-19 eras, the 2024-2025 RSV season saw a notable decline in overall hospitalizations for infants aged 0 to 7 months, as reported in the CDC's Morbidity and Mortality Weekly Report. Experts attributed this success to the extensive adoption of maternal RSV vaccines and nirsevimab. By cross-referencing data from the 2018-2020 seasons against 2024-2025 via networks like the RSV-Associated Hospitalization Surveillance Network and the New Vaccine Surveillance Network, across age brackets (0-7 months, 8-19 months, and 20-59 months), they found 11,681 RSV hospitalizations in the earlier period versus 6,708 in the later one, with rates per 1,000 kids dropping significantly in 2024-2025.
And this is the part most people miss—these preventive products aren't just for direct protection; they also ease the burden on healthcare systems by reducing emergency room visits, which could free up resources for other needs. It's a ripple effect worth pondering.
Read the full article at https://www.ajmc.com/view/infant-rsv-hospitalization-rates-drop-in-first-season-with-widespread-preventive-product-use.
- Strong Adoption Rates for Nirsevimab and RSVpreF, With No Increased Preterm Birth Risks Linked to RSVpreF
Approved in July 2023 for nirsevimab and August 2023 for the RSV prefusion F vaccine (RSVpreF), both achieved impressive uptake in their respective groups—infants and expectant mothers. The research reviewed outcomes for 647 pregnant women eligible for RSVpreF between 32 and 36 weeks gestation from October 15, 2023, to January 31, 2024; infants qualified if the birth parent hadn't been vaccinated at least two weeks prior. Factors boosting RSVpreF uptake (reaching 64.0%) included older maternal age, first-time parenthood, private insurance, non-Hispanic ethnicity, and prior vaccinations like flu or COVID shots. For nirsevimab, 40.4% of the 70.1% eligible infants were vaccinated, even among those whose parents opted out of standard prenatal shots, such as hepatitis B (notably, a topic of debate in its own right, as seen in ACIP discussions on vaccine schedules amid safety concerns).
But here's where it gets controversial—while high uptake is celebrated, is it ethical to influence vaccination choices through incentives like insurance perks, or could this pressure vulnerable families? It's a balancing act between health and autonomy.
Read the full article at https://www.ajmc.com/view/high-uptake-of-rsvpref-vaccine-nirsevimab-identified-with-no-preterm-risk.
- FDA Clears Clesrovimab as a New Defense Against RSV for Infants in Their Debut Season
June brought the approval of clesrovimab (Enflonsia, by Merck), giving infants and newborns entering their first RSV season an additional immunization choice to combat severe lower respiratory tract infections. The FDA's decision hinged on phase 2b/3 CLEVER trial data (NCT04767373), which revealed a 60.5% drop in RSV-related medically attended lower respiratory issues and an 84.3% cut in hospitalizations. As Octavio Ramilo, MD, from St. Jude Children's Research Hospital and a trial investigator, put it, 'Enflonsia offers easy dosing alongside robust evidence of slashed RSV incidence and hospital stays, positioning it as a hopeful new tool for safeguarding babies from RSV.'
To wrap it up, these 2025 highlights paint a promising picture of RSV prevention, yet they spark intriguing debates: Are we prioritizing the right groups, or overlooking long-term side effects? Do the costs of these vaccines justify widespread adoption, especially in resource-limited settings? And what about the ethical dilemmas of vaccinating pregnant women or newborns without their say? We'd love to hear your thoughts—agree, disagree, or add your own spin in the comments!
Newsletter
Want to stay on top of policy shifts, economic impacts, and value-driven insights? Sign up for AJMC to get expert analysis where clinical care meets health economics.
